Skip to main content

Table 5 Demographic comparison of retrospective studies on beta-blocker use in COPD

From: Effect of beta-blockers on exacerbation rate and lung function in chronic obstructive pulmonary disease (COPD)

Study Bhatt et al. [20] Rutten et al. [11] Short et al. [21] Van Gestel et al. [16] Current Study
MACRO4 STATCOPE3
N (on Beta blockers) 474 665 796 462 110 63
Age 66.8 64.7 69.8 69 67.3 63.4
% Men 60.1% 49.8% 42.7% 82.0% 67.6% 55.6%
Mean Pack years 56.8 n/a 44.3 n/a 59.4 49.1
% Current Smoker n/a 34.6% n/a 35.0% 21.6% 34.9%
FEV1 (L) 1.5 n/a n/a n/a 1.31 1.3
FEV1 mean % predicted 53.2% n/a 65% n/a 46.8% 45.8%
% GOLD 3/4 38.4% n/a n/a n/a 55.8% 61.9%
%Chronic bronchitis n/a n/a n/a n/a 50.5% 52.5%
% CAD or revasc 44.7% 38.3% (IHD) 70% (CV dz) 25% 50% 3%
% Diabetes 24.1% 24.1% 21% 17% 23% 5%
% Hypertension 84.4% 66.8% n/a 49% 82% 84%
% History of MI n/a 9.6% n/a 33% 38% 5%
  1. n/a data not available